Table 1.

Characteristics of study participants by treatment groups.

	Total		Allopurinol or febuxostat		Allopurinol plus fenofibrate or febuxostat plus fenofibrate		P-value
	N	%	n	%	n	%
Total	863		793		70
Sex							0.026
Male	789	91.4	720	90.8	69	98.6
Female	74	8.6	73	9.2	1	1.4
Age, years							0.014
–29	53	6.1	51	6.4	2	2.9
30–39	171	19.8	148	18.7	23	32.9
40–49	208	24.1	190	24.0	18	25.7
50–59	194	22.5	180	22.7	14	20.0
60–69	124	14.4	113	14.2	11	15.7
70–	113	13.1	111	14.0	2	2.9
Age (mean/SD)	50.6	14.9	50.9	15.1	46.9	12.0	0.012
Hypertension							0.013
No	469	54.3	421	53.1	48	68.6
Yes	394	45.7	372	46.9	22	31.4
Hyperlipidemia							<0.0001
No	563	65.2	554	69.9	9	12.9
Yes	300	34.8	239	30.1	61	87.1
Diabetes mellitus							0.806
No	736	85.3	677	85.4	59	84.3
Yes	127	14.7	116	14.6	11	15.7
Colchicine							0.683
No	661	76.6	606	76.4	55	78.6
Yes	202	23.4	187	23.6	15	21.4
Glucocorticoids							0.247
No	627	72.7	572	72.1	55	78.6
Yes	236	27.3	221	27.9	15	21.4
NSAIDs							0.156
No	628	72.8	572	72.1	56	80.0
Yes	235	27.2	221	27.9	14	20.0
HMG-CoA reductase inhibitor							0.780
No	820	95.0	753	95.0	67	95.7
Yes	43	5.0	40	5.0	3	4.3
Angiotensin receptor							0.424
No	812	94.1	744	93.8	68	97.1
Yes	51	5.9	49	6.2	2	2.9
Year of diagnosis							0.904
1995–2000	11	1.3	10	1.3	1	1.4
2001–2005	124	14.4	114	14.4	10	14.3
2006–2010	215	24.9	195	24.6	20	28.6
2011–2015	343	39.7	315	39.7	28	40.0
2016–2018	170	19.7	159	20.1	11	15.7

SD: standard deviation; NSAIDs: nonsteroidal anti-inflammatory drugs; HMG-CoA: 3-hydroxy-3-methylglutaryl-CoA.